Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells
Takashi Saigawa, Kiminori Kato, Takuya Ozawa, Ken Toba, Yashiro Makiyama, Shiro Minagawa, Shigeo Hashimoto, Tatsuo Furukawa, Yuichi Nakamura, Haruo Hanawa, Makoto Kodama, Nobuhiko Yoshimura, Hiroshi Fujiwara, Osamu Namura, Masakazu Sogawa, Jun-ichi Hayashi, Yoshifusa Aizawa, Takashi Saigawa, Kiminori Kato, Takuya Ozawa, Ken Toba, Yashiro Makiyama, Shiro Minagawa, Shigeo Hashimoto, Tatsuo Furukawa, Yuichi Nakamura, Haruo Hanawa, Makoto Kodama, Nobuhiko Yoshimura, Hiroshi Fujiwara, Osamu Namura, Masakazu Sogawa, Jun-ichi Hayashi, Yoshifusa Aizawa
Abstract
Background: There have been a number of recent reports on the use of autologous bone marrow implantation (BMI) in the treatment of peripheral arterial disease, with a clinical response rate of approximately 70%. However, the factors that influence efficacy have not yet been clarified. We have analyzed the relationship between the number of implanted bone marrow cells and the clinical efficacy of BMI.
Methods and results: Eight patients with arteriosclerosis obliterans were treated with BMI. Bone marrow was aspirated from the ilium (500-1,000 ml), the mononuclear cells were separated and then were implanted. The clinical effectiveness of BMI was evaluated by assessing changes in the ankle-brachial pressure index (ABI) and the transcutaneous oxygen pressure (TcO2) between the pre-treatment baseline, with follow-up testing at 4 weeks. These changes were defined as DeltaABI and DeltaTcO2. The mean number of CD34-positive cells was 1.04+/-0.60 x10(6) /kg body weight. There was a strong correlation between the number of CD34-positive cells and DeltaABI (r=0.754, p=0.028).
Conclusions: It is likely that the number of implanted CD34-positive cells is one of the primary factors that influence the clinical efficacy of BMI.
Source: PubMed